Featured Oncology News
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
FDA Rejects Immunomedics Breast Cancer Drug, Extending Long Regulatory Drought
Celgene, Sold For $74 Billion, Leaves A Legacy Of Chutzpah In Science And Drug Pricing
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
San Francisco, CA
Amsterdam, The Netherlands
Santa Monica, CA
Washington, DC
Orlando, FL
Atlanta, GA
Orlando, FL
Geneva, Switzerland
Denver, CO
Chicago, IL
RAI Amsterdam, The Netherlands
Lugano, Switzerland
San Francisco, CA
Buenos Aires, Argentina
Orlando, FL
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Gene-Expression Profiling Raises Costs for Cancer Ca...
January 23rd 2019 by Tomasz M. Beer, MD, FACP
This is an excellent reminder that genomic testing is fundamentally no different from any other dia...
Read More
Association Between Reimbursement Incentives and Phy...
January 22nd 2019 by Thomas Marsland, MD
Financial incentives have and always will drive healthcare. There is no free lunch. This report foc...
Read More
AbbVie Provides Update on Phase 3 Study of Ibrutinib...
January 22nd 2019 by Howard S. Hochster, MD
Another phase 3 trial of Gem-Abraxane with or without your favorite targeted agent. No particular ...
Read More
FDA Accepts Roche’s Supplemental Biologics License...
January 17th 2019 by H. Jack West, MD
This application is based on the results of the IMpower130 trial of first line carbo/nab-paclitaxel...
Read More
Exelixis Announces U.S. FDA Approval of CABOMETYX® ...
January 15th 2019 by Howard S. Hochster, MD
Another TKI for HCC! We now have 3 agents with variable tolerability profiles. Good news for pati...
Read More
Researchers Uncover Major Clue In Predicting Respons...
January 14th 2019 by Tomasz M. Beer, MD, FACP
It is fascinating to see that greater complexity of cancer, typically associated with more aggressi...
Read More
OBR Green